Mirati Therapeutics, Inc.
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (38.4% 1y) (0.0% 2d) (-0.1% 3d) (0.0% 7d) (-41.54% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 4,117,670,342
http://www.mirati.com
Sec Filling | Patents | 111 employees
(US) Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
cancer immunology genetic
add to watch list Paper trade email alert is off
Press-releases
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | $3.8 0.26% 3.5K
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
Corcept Appoints Roberto Vieira as President, Oncology
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
CORT M | $23.18 0.78% 400K
|
Health Technology
|
| O: 0.6%
H: 2.48%
C: 2.48%
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Published: 2024-01-23 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $90.79 0.79% 1.7M
|
Finance
|
| O: -0.07%
H: 1.38%
C: 1.25%
EVR | $186.155 0.35% 79K
|
Finance
|
| O: 0.35%
H: 0.29%
C: -0.26%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: 0.89%
acquisition
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12 lung cancer cell treatment advanced
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
GNMSF | $281.02 210
|
Health Technology
|
| O: 6.62%
H: 2.29%
C: -0.06%
ZLAB | $14.175 3.32% 320K
|
Health Technology
|
| O: 8.3%
H: 0.02%
C: -2.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.57%
NVCR | $12.23 1.49% 280K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: -6.94%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.21%
C: -0.48%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.27%
H: 0.14%
C: -3.34%
GMAB | $28.38 -0.53% 140K
|
Health Technology
|
| O: 7.35%
H: 0.44%
C: -2.18%
results
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics financial results
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: -0.9%
H: 1.08%
C: 0.61%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.2%
H: 0.43%
C: -0.38%
KURA | $17.83 -0.89% 930K
|
Health Technology
|
| O: 0.13%
H: 6.0%
C: 5.25%
ko-2806 collaboration therapeutics agreement
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News 0 d | $90.79 0.79% 1.7M
|
Finance
|
| O: 0.83%
H: 0.0%
C: 0.0%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | $3.8 0.26% 3.5K
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $47.895 0.12% 4.6M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Last 48 Hours Insiders Buying
QCRH | $55.405 1.33% 13K
|
Finance
|
18:01
RVP P 15363 | $1.04 14K
|
Health Technology
|
18:00
VUZI | $1.33 9.02% 540K
|
Electronic Technology
|
18:00
TPL P 3 | $592.6 1.31% 22K
|
Miscellaneous
|
15:00
RELL | $10.24 3.85% 36K
|
Electronic Technology
|
13:30
IZEA | $2.53 20K
|
Technology Services
|
00:00
RKT P 383 | $11.735 3.12% 640K
|
Finance
|
22:30
CTRN P 18090 | $22.39 0.09% 33K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 44K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.07 -0.58% 840K
|
Health Technology
|
16:30
RMCF | $3.53 1.7K
|
Consumer Non-Durables
|
20:10